Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $6.6 million.

  • Krystal Biotech's Cost of Revenue rose 3319.86% to $6.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.0 million, marking a year-over-year increase of 1488.96%. This contributed to the annual value of $23.0 million for FY2025, which is 1489.46% up from last year.
  • Krystal Biotech's Cost of Revenue amounted to $6.6 million in Q4 2025, which was up 3319.86% from $4.3 million recorded in Q3 2025.
  • Over the past 5 years, Krystal Biotech's Cost of Revenue peaked at $7.2 million during Q2 2025, and registered a low of $223000.0 during Q3 2023.
  • In the last 3 years, Krystal Biotech's Cost of Revenue had a median value of $5.0 million in 2024 and averaged $4.6 million.
  • In the last 5 years, Krystal Biotech's Cost of Revenue skyrocketed by 289730.94% in 2024 and then tumbled by 3622.08% in 2025.
  • Krystal Biotech's Cost of Revenue (Quarter) stood at $2.9 million in 2023, then surged by 72.38% to $4.9 million in 2024, then skyrocketed by 33.2% to $6.6 million in 2025.
  • Its Cost of Revenue stands at $6.6 million for Q4 2025, versus $4.3 million for Q3 2025 and $7.2 million for Q2 2025.